Glycomimetics INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Crescent Biopharma details its oncology pipeline, strategic partnerships, and financial position in its 2025 annual report, highlighting significant capital raises and ongoing clinical development.
GlycoMimetics plans to merge with Crescent Biopharma following a strategic review prompted by disappointing clinical trial results, aiming to maximize shareholder value.
GlycoMimetics, Inc. released its annual report on Form 10-K, detailing its financial performance and progress in drug development for the fiscal year ended December 31, 2023.